Stevanato Group has introduced the new patented on-body delivery system Vertiva for several subcutaneous therapies.

Designed to be adapted to different delivery profiles, the device facilitates the administration of biologics and small-molecule drugs.

The new system holds the potential to switch between basal and bolus injections.

It is programmed to deliver micro-precision basal doses and full-content bolus injections and can be used for various therapies including oncology, immunology, pain diseases and cardiovascular and metabolic disorders.

Vertiva features a pre-filled and pre-loaded 3mL ISO cartridge, as well as a multi-use controller. Both parts communicate through a patented magnetically coupled drive mechanism.

The device simplifies treatment initiation for patients by preloading and sealing the cartridge into the pod during factory assembly, allowing one to conduct administrations at home and offering connectivity options for digital health applications.

The pod and controller can be easily separated once the treatment is completed. The controller can also be reused to reduce the environmental impact of electronic components.

The Vertiva platform offers the flexibility to support various customisations, including primary packaging format for larger injection volumes, delivery duration and user interface.

Stevanato is currently working on Vertiva‘s design to accommodate various volumes of up to 10mL.

Stevanato Group drug delivery systems vice-president Steven Kaufman said: “The Vertiva on-body delivery system supports pharma companies in increasing the accessibility of in-home care and administered treatment options, which can ultimately lead to an improved patient experience.”

The collaboration between Stevanato Group and Thermo Fisher Scientific will be utilised to introduce Vertiva to the market.

The platform will be offered as a fill-and-finish solution to streamline the handling of the pharmaceutical supply chain.